Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;56(11):1304-19.
doi: 10.1097/DCR.0b013e3182a479f9.

Diabetes mellitus and colorectal cancer prognosis: a meta-analysis

Katherine T Mills  1 , Charles F Bellows, Aaron E Hoffman, Tanika N Kelly, Giuseppe Gagliardi
Affiliations
Review

Diabetes mellitus and colorectal cancer prognosis: a meta-analysis

Katherine T Mills et al. Dis Colon Rectum. 2013 Nov.

Abstract

Background: Diabetes mellitus is associated with an increased incidence of colorectal cancer, but the impact of diabetes mellitus on colorectal cancer prognosis is not clear.

Objective: We conducted a meta-analysis of observational studies to examine the association between preexisting diabetes mellitus and colorectal cancer all-cause mortality, cancer-specific mortality, and recurrence.

Data sources: Medline and Embase were searched through August 22, 2012.

Study selection: We included studies reporting all-cause mortality, cancer-specific mortality, disease-free survival, or recurrence in patients who have colorectal cancer according to diabetic status.

Intervention: Meta-analyses were performed by the use of random-effects models.

Main outcome measures: The primary outcomes measured were all-cause mortality, cancer-specific mortality, and disease-free survival.

Results: Twenty-six articles met our inclusion criteria. Patients with colorectal cancer who had diabetes mellitus had a 17% increased risk of all-cause mortality (relative risk, 1.17; 95% CI, 1.09-1.25) and a 12% increased risk of cancer-specific mortality (relative risk, 1.12; 95% CI, 1.01-1.24) in comparison with those who did not have diabetes mellitus. Those with diabetes mellitus also had poorer disease-free survival (relative risk, 1.54; 95% CI, 1.08-2.18) compared with their nondiabetic counterparts. In subgroup analyses, diabetes mellitus was associated with all-cause mortality in both rectal (relative risk, 1.24; 95% CI, 1.07-1.29) and colon cancer patients (relative risk, 1.17; 95% CI, 1.07-1.29). Sensitivity analyses including only patients with nonmetastatic disease identified stronger associations between diabetes mellitus and both all-cause (relative risk, 1.32; 95% CI, 1.21-1.44) and cancer-specific (relative risk, 1.27; 95% CI, 1.06-1.52) mortality.

Limitations: Some studies had short follow-up or did not report mean or median follow-up. The included studies were heterogeneous in study population, diabetes mellitus diagnostic criteria, and outcome ascertainment.

Conclusion: Patients with colorectal cancer who have diabetes mellitus are at greater risk for all-cause and cancer-specific mortality and have worse disease-free survival than those who do not have diabetes mellitus. Studies are warranted to determine whether the proper treatment could attenuate the excess mortality among patients with colorectal cancer who have diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of study selection
Figure 2
Figure 2
Meta-analysis of the effect of pre-existing diabetes on all-cause mortality (a), cancer-specific mortality (b), disease-free survival (risk of recurrence or death) (c) and recurrence rate (d). * Males Only; † Females Only; ‡ Stage 3 Cancer; § Stage 4 Cancer; Colon Cancer; // Rectal Cancer
Figure 2
Figure 2
Meta-analysis of the effect of pre-existing diabetes on all-cause mortality (a), cancer-specific mortality (b), disease-free survival (risk of recurrence or death) (c) and recurrence rate (d). * Males Only; † Females Only; ‡ Stage 3 Cancer; § Stage 4 Cancer; Colon Cancer; // Rectal Cancer
Figure 2
Figure 2
Meta-analysis of the effect of pre-existing diabetes on all-cause mortality (a), cancer-specific mortality (b), disease-free survival (risk of recurrence or death) (c) and recurrence rate (d). * Males Only; † Females Only; ‡ Stage 3 Cancer; § Stage 4 Cancer; Colon Cancer; // Rectal Cancer
Figure 2
Figure 2
Meta-analysis of the effect of pre-existing diabetes on all-cause mortality (a), cancer-specific mortality (b), disease-free survival (risk of recurrence or death) (c) and recurrence rate (d). * Males Only; † Females Only; ‡ Stage 3 Cancer; § Stage 4 Cancer; Colon Cancer; // Rectal Cancer
Figure 3
Figure 3
Meta-analysis of the effect of pre-existing diabetes on all-cause mortality (a) and cancer-specific mortality (b) stratified by cancer type. * Stage 3 Cancer; † Stage 4 Cancer
Figure 3
Figure 3
Meta-analysis of the effect of pre-existing diabetes on all-cause mortality (a) and cancer-specific mortality (b) stratified by cancer type. * Stage 3 Cancer; † Stage 4 Cancer
See this image and copyright information in PMC

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. [Accessed December 17 2012];GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Available from: http://globocan.iarc.fr.
    1. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86:s836–842. - PubMed
    1. Berster JM, Göke B. Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem. 2008;114:84–98. - PubMed
    1. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila) 2011;4:1873–1883. - PubMed
    1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31–40. - PubMed